Passage Bio, a genetic medicines company, reported significant progress in its PBFT02 gene therapy trials for FTD-GRN. The company revealed promising interim data that indicates PBFT02's potential as a leading progranulin-raising therapy.
Patient enrollment in the trials is on track, and robust preclinical data has been presented at key scientific conferences, reinforcing the therapeutic potential of PBFT02.
The company is positioned to achieve critical milestones, supported by a strong financial position that ensures operations until mid-2026. This extended cash runway provides stability for ongoing development efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.